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Mer belongs to the Mer/Axl/Tyro3 receptor tyrosine
kinase family, which regulates immune homeostasis in
part by triggering monocyte ingestion of apoptotic cells.
Mutations in Mer can also cause retinitis pigmentosa,
again due to defective phagocytosis of apoptotic mate-
rial. Although, some functional aspects of Mer have been
deciphered, how receptor activation lead to the physio-
logical consequences is not understood. By using yeast
two-hybrid assays, we identified the carboxyl-terminal
region of the guanine nucleotide-exchange factor (GEF)
Vav1 as a Mer-binding partner. Unlike similar (related)
receptors, Mer interacted with Vav1 constitutively and
independently of phosphotyrosine, yet the site of bind-
ing localized to the Vav1 SH2 domain. Mer activation
resulted in tyrosine phosphorylation of Vav1 and re-
lease from Mer, whereas Vav1 was neither phosphoryl-
ated nor released from kinase-dead Mer. Mutation of the
Vav1 SH2 domain phosphotyrosine coordinating Arg-
696 did not alter Mer/Vav1 constitutive binding or Vav1
tyrosine phosphorylation but did retard Vav1 release
from autophosphorylated Mer. Ligand-dependent acti-
vation of Mer in human monocytes led to Vav1 release
and stimulated GDP replacement by GTP on RhoA fam-
ily members. This unusual constitutive, SH2 domain-de-
pendent, but phosphotyrosine-independent, interaction
and its regulated local release and subsequent activa-
tion of Rac1, Cdc42, and RhoA may explain how Mer
coordinates precise cytoskeletal changes governing the
ingestion of apoptotic material by macrophages and pig-
mented retinal epithelial cells.
The Mer receptor tyrosine kinase was identified by molecular
rather than functional assays (1), and hence its physiological
function and that of its two family members, Axl and Tyro3,
has been elucidated slowly. Mer is primarily expressed in
monocytes and cells of epithelial and reproductive origin with
the highest levels of Mer mRNA detected in testis, ovary, pros-
tate, kidney, lung, and peripheral blood monocytes (1, 2). Mer is
not expressed in normal B- and T-cells but Mer mRNA expres-
sion was detected in variety of human tumor cells, including
neoplastic T and B cell lines; it is also present in the majority
of childhood acute lymphoid leukemia samples tested.1 The
Mer extracellular region, like Axl and Tyro3, comprises two
immunoglobulin-like and two fibronectin type III repeats, a
transmembrane domain, and an intracellular kinase domain
with an unusual KWIAIES motif (1, 2). Biochemical purifica-
tion identified Gas-6 as a ligand for Axl and Tyro3; subsequent
studies showed binding to Mer, but the affinity of Gas6 for Mer
is considerably lower (29 nM) than its affinity for Axl and
Tyro-3 (0.4 and 2.9 nM, respectively) (3–6).
To investigate the physiological function of Mer, our group
generated a knockout mouse deleting the Mer tyrosine kinase
domain (Merkd) (7). Merkd mice were extremely sensitive to
endotoxin (lipopolysaccharide) treatment exhibiting excessive
TNF- production by monocytes resulting in lethal endotoxic
shock. The spleens of Merkd mice were enlarged in some ani-
mals demonstrating accumulation of apoptotic debris (7), and
the spleens were markedly enlarged in Mer, Axl, and Tyro3
triple-knockout mice (8). Subsequently, a crucial role of Mer in
phagocytosis of apoptotic cells was demonstrated in Merkd
mice. Monocytes bound but did not ingest apoptotic thymo-
cytes, and the thymuses of dexamethasone-treated mice exhib-
ited a marked diminution of apoptotic cell clearance (9). Phag-
ocytosis of other particles was intact indicating a selective
defect for apoptotic material in these animals (9). Indeed, the
triple mutant mice lacking Mer, Axl, and Tyro3 receptors had
very high levels of apoptotic cells in many organs, including
liver, kidney, muscle, brain, spinal cord, and eye (10). Failure
to ingest apoptotic self material led to evidence of autoimmu-
nity in Merkd mice (7, 11) and evidence of profound autoactiva-
tion of the immune system in the triple-knockout mice (10).
The Royal College of Surgeons (RCS)2 rat exhibits a progres-
sive and postnatal loss of vision because of a failure of retinal
pigment epithelial (RPE) cells to ingest shed outer segments of
photoreceptor cells (12). This genetic defect was traced to a
deletion of a Mer splice acceptor site next to the second exon
resulting in the loss of functional Mer. Gas6-mediated activa-
tion of Mer can result in the ingestion of shed photoreceptor
outer segments by the cultured rat RPE cells (13), and the
retinal dystrophy phenotype can be corrected by delivery of
replication-deficient adenovirus encoding rat Mer gene to the
eyes of young RCS rats (14, 15). Subsequently, separate muta-
tions in Mer each predicted to abrogate Mer tyrosine kinase
activity were identified in three families with retinitis pigmen-
tosa (16). Individuals harboring these mutations suffer from
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progressive loss of vision, presumably due to defective phago-
cytosis of shed photoreceptor cells by RPE cells (16).
To study Mer function we stably transfected the IL-3-de-
pendent murine hematopoietic cell line 32Dc13 (32D) with an
EGF receptor extracellular and transmembrane domain-Mer
cytoplasmic domain chimera. In these cells, EGF-dependent
Mer signaling prevented apoptosis upon IL-3 and serum with-
drawal. In contrast to transfected full-length EGF receptor and
other receptor tyrosine kinases, Mer prevented 32D cell apo-
ptosis without stimulating cellular proliferation. When com-
bined with IL-3, Mer signaling produced dramatic shape
changes, suggesting involvement of Mer tyrosine kinase in
cytoskeletal remodeling (17). However, the mechanism by
which Mer signaling brings about cytoskeletal changes in ex-
perimental (32D) or physiological (monocytes or macrophages)
processes remains obscure. Here we demonstrate that Mer
interacts constitutively with the SH2 domain of the guanine
nucleotide exchange factor (GEF), Vav1. Surprisingly, this SH2
domain/Mer interaction is phosphotyrosine-independent. Mer
activation leads to tyrosine phosphorylation and release of
Vav1 and activation of Rho family members. This unusual
constitutive, SH2 domain-dependent but phosphotyrosine-in-
dependent interaction and release may provide the circum-
scribed local cytoskeletal control necessary to trigger ingestion
of apoptotic material bound to the surface of phagocytic mono-
cytes or pigmented epithelial cells.
EXPERIMENTAL PROCEDURES
Plasmids and Site-directed Mutagenesis—A chimeric receptor was
constructed wherein the extracellular domain of Mer was replaced with
a ligand binding and transmembrane domain of the rat EGF receptor
(Fig. 1A), using a suitable SalI restriction site at juxtamembrane region
of these two receptors. The entire coding region of chimeric receptor of
1142 amino acids was subcloned into pLXSN, a mammalian retroviral
expression vector (Clontech). This EGFR-Mer Chimeric receptor was
named EMC. For construction of the “bait” plasmid pNCMY, 290 amino
acids of the carboxyl-terminal intracellular region of Mer (amino acids
546–836), which includes the entire kinase domain, was amplified by
PCR and inserted in-frame to the Gal4 DNA-binding domain of the
pAS2–1 vector (Fig. 1A). Full-length Vav1 and all the Vav1 truncation
constructs were generated by PCR amplification using pJC11 plasmid
(kindly provided by Prof. C. J. Der) as template and Pfx polymerase,
which has proofreading ability (Invitrogen). The PCR products were
digested with XhoI and HindIII and subcloned into the corresponding
sites of pcDNA4.1/Myc-His vector (Invitrogen) in-frame with a myc
epitope-encoding region (Fig. 1B). The Mer truncation constructs AMer
(aa 529–999), BMer (aa 621–999), CMer (aa 690–999), DMer (aa 529–
696), EMer (aa 755–999), and FMer (aa 777–999) were generated by
PCR amplification using full-length Mer as template and Pfx polymer-
ase. The PCR products were digested with XhoI and HindIII and sub-
cloned into the corresponding sites of pcDNA4.1/Myc-His vector. The 3
primers used in Mer truncation constructs had a stop codon thus no tag
was present in AMer, BMer, CMer, DMer, EMer, and FMer (Fig. 5A).
For expression of GST-Mer fusion proteins, intracellular region (car-
boxyl-terminal 415 amino acids) of Mer was PCR-amplified using Pfx
polymerase. The PCR product was digested with BamHI and SalI and
subcloned into pGEX-4T vector in appropriate reading frame (Fig. 1A).
Mutagenesis of Mer and Vav1 proteins was performed using GeneEdi-
tor in vitro site-directed mutagenesis system (Promega). All the plasmid
constructs were sequenced to confirm the authenticity.
Two-hybrid Screening—Matchmaker two-hybrid system-2 was used
for identification of interacting clones (Clontech). Y190 cells trans-
formed with pNCMY produced expected fusion proteins of 69 kDa,
detected by Western blotting with an antibody against the GAL4 DNA-
binding domain (Upstate Biotechnology Inc.). A human bone marrow
cDNA library was screened. 1  106 transformants were plated on
SD/-Trp/-Leu/-His/-Ade plates. The colonies that grew on these plates
were further screened and “true positive” were selected, based on the
criterion that these colonies could not induce His or -galactosidase
production when plasmid DNA isolated from these “positive” colonies
was transformed into yeast cells carrying pAS2–1 vector. To further
confirm, the colony-lift -galactosidase filter assay was performed ac-
cording to manufacturer’s protocol (Clontech).
Antibodies, Cell Lines, Immunoprecipitations, and Immunoblot Anal-
ysis—A polypeptide containing the carboxyl-terminal 90 amino acids of
Mer was expressed as GST fusion protein in DH5 Escherichia coli
strain and plated onto ampicillin plates. Colonies were picked and
grown overnight in 10 ml of LB containing ampicillin. Overnight grown
culture was added to 300 ml of fresh LB containing ampicillin and
grown for 2 h, which was followed by isopropyl-1-thio--D-galactopyr-
anoside addition (0.1 mM final concentration). Culture was grown for 2
more h, and cells were harvested, lysed in Lysis Buffer, containing 25
mM Tris (pH 7.5), 150 mM NaCl, 0.4% Triton X-100, 1 mM DTT, 15%
glycerol, phosphatase inhibitors (10 mM NaF, 1 mM Na2VO4), and pro-
tease inhibitor mix (25 g/ml leupeptin, 25 g/ml trypsin inhibitor, 25
g ml pepstatin, 25 g/ml aprotinin, 10 mM benzamidine, 1 mM phen-
ylmethylsulfonyl fluoride). Lysates were incubated with glutathione
beads for 2 h, followed by washing with lysis buffer and elution in PBS
containing 10 mM glutathione. Eluted protein was dialyzed against 50
mM Tris, pH 7.5, 10% glycerol, 100 mM NaCl, and 1 mM DTT, to remove
all glutathione. The purified polypeptide was then used to generate
rabbit polyclonal antibody. Anti-Mer Ab2 (Clone 110) was obtained
from FabGennix International. Anti-Vav1 antibody was purchased
from UBI. Anti-phosphotyrosine (RC20) antibodies were purchased
from BD Transduction Laboratories. Anti-Rac1, anti-RhoA, and anti-
Cdc42 antibodies were purchased from Santa Cruz Biotechnology. Goat
anti-rabbit immunoglobulin G (IgG)-HRP, and goat anti-mouse IgG-
HRP antibodies were purchased from Amersham Biosciences. Anti-myc
monoclonal antibody was obtained from Invitrogen. Human SV40-
transformed embryonic kidney 293T cells were maintained in Dulbec-
co’s modified Eagle’s medium containing 10% fetal calf serum. 32D cells
were maintained in RPMI medium containing 15% fetal calf serum and
5% WEHI cell-spent media (IL-3). 293T cells were transfected using
FuGENE (Invitrogen) as per the manufacturer’s protocol. Thirty-two
hours after transfection, cells were serum-starved for 16 h and treated
for 20 min with EGF (100 ng/ml). Cells were harvested, immediately
washed in ice cold phosphate-buffered saline (PBS), and lysed in recep-
tor lysis buffer (RLB), containing 25 mM Tris (pH 7.5), 175 mM NaCl, 1%
Triton X-100, 1 mM DTT, 15% glycerol, phosphatase inhibitors (10 mM
NaF, 1 mM Na2VO4), and protease inhibitor mix (25 g/ml leupeptin, 25
g/ml trypsin inhibitor, 25 g/ml pepstatin, 25 g/ml aprotinin, 10 mM
benzamidine, 1 mM phenylmethylsulfonyl fluoride). Equivalent
amounts of protein were incubated with respective primary antibodies
for 2 h or overnight at 4 °C, followed by incubation with protein A/G-
Sepharose (Santa Cruz Biotechnology) for 30 min. The beads were
washed three times in the RLB buffer, resuspended in the appropriate
volume of Laemmli gel loading buffer, and subjected to SDS-polyacryl-
amide gel electrophoresis. The proteins were electrotransferred to ni-
trocellulose membranes and blocked in 3% bovine serum albumin (for
pTyr blots) or 5% milk in TBST buffer (Tris-buffered saline, pH 7.5,
0.1% Tween 20) for 1 h. Blocked filters were probed with primary
antibodies in the same buffer, followed by secondary antibody conju-
gated to HRP in blocking solution and developed using enhanced chemi-
luminescence (ECL) detection (Amersham Biosciences). The blots were
re-probed with a second set of antibodies (anti-Mer or anti-myc) to
confirm the presence of respective proteins.
Purification of Recombinant Proteins LVav and KVav from Sf9 Insect
Cells—Baculovirus expression constructs were generated using the
pFast Bac method (Invitrogen-Brl). SH3-SH2-SH3 and SH3-SH3 do-
mains of Vav1 were PCR-amplified using CVav and JVav as templates
and were subcloned along with a 5 six-histidine tag into the XbaI and
SalI sites of pDR120 vector, named as LVav and KVav, respectively.
Expression of LVav and KVav in recombinant baculovirus-infected Sf9
insect cell extracts was confirmed by Western analysis with anti-poly-
histidine antibodies. 200 ml of baculovirus-infected Sf9 cells were used
for the purification of the protein. Cells were harvested 3 days following
infection with the virus. Cell pellets from (6  107 cells) were suspended
in an extraction buffer containing 10 mM Tris-HCl, pH 8.0, 50 mM
sodium phosphate, pH 8.0, 0.5 M NaCl, 10% glycerol, 20 mM -mercap-
toethanol, and protease inhibitor mixture (Roche Applied Science). The
extract was sonicated for 1-min pulses and then clarified by centrifu-
gation twice at 15,000  g for 15 min. The supernatant was added to 2
ml (50% slurry) of pre-equilibrated Talon affinity beads (Clontech).
Binding was done for 2 h in the cold room. The unbound proteins were
removed by centrifugation at 2000 rpm for 2 min. The beads were
washed with 10 ml of extraction buffer thrice. After final wash the
beads were transferred to 15-ml chromatographic columns (Bio-Rad).
The beads were subsequently washed with 10 bed volumes of wash
buffer containing 50 mM sodium phosphate (pH 7.0), 500 mM NaCl, 20
mM imidazole, 10% glycerol, 20 mM -mercaptoethanol. The bound
proteins were eluted in buffer containing 20 mM Tris HCl, pH 8.0, 100
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mM NaCl, 100 mM imidazole, 10% glycerol, and 20 mM -mercaptoeth-
anol and collected as 0.5-ml fractions. The fractions were analyzed by
SDS-PAGE and Coomassie Blue staining. The fractions containing the
purified protein were pooled and dialyzed against 50 mM Tris, pH 7.5,
10% glycerol, 100 mM NaCl, and 1 mM DTT. The protein concentration
was determined by using the Bradford method. Small aliquots of the
purified protein were stored at 80 °C.
Purification of GST-Mer and in Vitro Binding Assay—GST-Mer con-
struct was transformed into BL21(DE3) cells and plated onto ampicillin
plates. Colonies were picked and grown overnight in 10 ml of LB
containing ampicillin. Culture, grown overnight, was added to 300 ml of
fresh LB containing ampicillin and grown for 2 h, which was followed by
isopropyl-1-thio--D-galactopyranoside addition (0.1 mM final concen-
tration). Culture was grown for 4 more hours, and cells were harvested,
lysed in lysis buffer, containing 25 mM Tris (pH 7.5), 150 mM NaCl, 0.4%
Triton X-100, 1 mM DTT, 15% glycerol, phosphatase inhibitors (10 mM
NaF, 1 mM Na2VO4), and protease inhibitor mix. Lysates were incu-
bated with glutathione beads for 2 h, followed by washing with lysis
buffer and elution in PBS containing 10 mM glutathione. Eluted protein
was dialyzed against 50 mM Tris, pH 7.5, 10% glycerol, 100 mM NaCl,
and 1 mM DTT, to remove all glutathione.
For the in vitro binding assay, 50 nM purified LVav or KVav were
added to Talon beads resuspended in modified RLB containing 25 mM
Tris (pH 7.5), 175 mM NaCl, 0.4% Triton X-100, 1 mM DTT, 15%
glycerol, 1% protease-free bovine serum albumin, and protease inhibi-
tor mix. After 1 h, Talon beads were washed to remove all unbound
proteins. Purified GST-Mer (50 mM) was added to similarly treated
Talon beads without Vav1 domain proteins or to Talon beads with
bound LVav or KVav. Following incubation on ice for 30 min and then
incubation with shaking at 4 °C for 1 h, beads were washed thrice with
lysis buffer. Bound protein was dissociated from beads by boiling in
SDS sample buffer and assessed by gel electrophoresis, transfer, and
detection by immunoblotting with anti-Mer antibody. In a control ex-
periment, the use of NaCl concentration above 175 mM prevented de-
tection of GST-Mer/LVav interaction.
Assay for Detection of Activated Rac1, RhoA, and Cdc42—The gluta-
thione-Sepharose beads conjugated with GST-Pak (PBD) or GST-Rok
(RBD) were used as specific probes for in vitro binding assays of acti-
vated Rac1, Cdc42, and RhoA, respectively. Stable cell lines expressing
EMC and kdEMC were grown overnight in serum-free media with 5%
WEHI cells spent media (IL-3). Next day, cells were stimulated with
EGF ligand for 20 or 30 min. Cells were lysed in MLB buffer (25 mM
HEPES, pH 7.5, 150 mM NaCl, 1% Igepal CA-630, 10 mM MgCl2, 1 mM
EDTA, 10% glycerol, protease, and phosphatase inhibitor mixture).
Samples of 500 g of protein lysates were mixed with 20 l of PBD
beads and incubated at 4 °C for 45 min. The beads were washed three
times in MLB buffer and analyzed by Western blotting to detect the
bound Rac1 and Cdc42 GTPases. For RhoA, cells were lysed in RLB
buffer (50 mM Tris, pH 7.2, 500 mM NaCl, 1% Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, 10 mM MgCl2, 1 mM EDTA, 10% glycerol,
protease, and phosphatase inhibitor mixture). Samples of 500 g of
protein lysates were mixed with 30 l of RBD beads and incubated at
4 °C for 45 min. The beads were washed three times in wash buffer (50
mM Tris, pH 7.2, 150 mM NaCl, 1% Triton X-100, 0.1 mM phenylmeth-
ylsulfonyl fluoride, 10 mM MgCl2, 10% glycerol, protease, and phospha-
tase inhibitor mixture) and analyzed by Western blotting.
Isolation of Human Macrophages—Human blood (buffy coat) was
diluted to 50% with PBS and mixed gently. The mixture was gently
layered over 50 ml of Ficoll (Histopaque-1077, Sigma). After centrifu-
gation at 2000 rpm for 30 min the mononuclear cell layer was collected
and washed four times with PBS and plated in RPMI media containing
10% fetal bovine serum. After 2 h of incubation, adherant monocytes
and macrophages were retained and allowed to grow for 7–10 days in
RPMI media, before Gas6 treatment.
RESULTS
Mer Interacts with GEF and Vav1—Downstream effectors of
Mer signaling were sought by yeast two-hybrid methods (18). A
human bone marrow cDNA library was screened with the Mer
cytoplasmic domain (pNCMY vector, Fig. 1A) as bait. Of nine
positive colonies, three encoded the carboxyl-terminal SH3-
SH2-SH3 domains of Vav1 (CVavN depicted in Fig. 1B). This
prototypic GEF is a 97-kDa protein with multiple structural
motifs (Fig. 1B), including, from the carboxyl to the amino
termini, the following domain/motifs: a calponin homology
(CH), an acidic region (Ac), a Dbl-homology (DH), a pleckstrin-
homology (PH), a zinc finger domain (ZF), a short proline-rich
region (PR), and two SH3 domains flanking a single SH2 region
(21). Clones for two other Mer interacting proteins, Grb2 and
Shc (19, 20), were also isolated.
Because Gas6 had not yet been identified as a ligand for Axl,
Tyro3, or Mer when our studies began, we created a ligand-
activated EGFR-Mer-chimera (EMC), using the rat EGF recep-
tor extracellular and transmembrane domains and the Mer
intracellular domain (Fig. 1A). EMC was stably transfected
into mouse 32D cells, and, when activated with ligand, it pre-
vented apoptosis upon IL-3 withdrawal from this IL-3-requir-
ing cell line. Unlike most receptor tyrosine kinases, Mer acti-
vation did not stimulate proliferation, but it did alter cell
adherence and shape in these normally suspension-growing
cells (17). This positive effect on cytoskeletal components cou-
pled with the fact that Mer knockout mice exhibited defects in
local cytoskeletal regulation (phagocytosis), and the strong pos-
itive yeast two-hybrid signal, led us to pursue the interaction
and potential physiological role of the Mer/Vav1 complex.
For these studies full-length Vav1 and truncated constructs
were generated using vector pcDNA4 (depicted in Fig. 1B) and
tagged with an myc epitope. Each construct gave generally
equivalent expression when transfected into 293T cells (Fig.
FIG. 1. Domain structure of Mer and Vav1. A, schematic of Mer,
Mer chimera, and the cytoplasmic domain constructs used for yeast
two-hybrid and in vitro binding assays. B, domain structure of Vav1 and
schematics of the truncation, deletion, and structural mutants used for
co-transfections. C, Western analysis for expression of Vav1 and its
myc-tagged derivatives. D, Western analysis for expression of Vav1 and
its untagged derivative AVav.
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1C). The AVav construct, which was not myc-tagged and thus
was detected using Vav1 antibodies, also expressed equiva-
lently to Vav1 (Fig. 1D). Vav1 interaction with the Mer intra-
cellular domain was studied by co-transfection with either
EMC or an EMC with a K619M site-directed mutation that
destroyed kinase activity (kinase-dead EMC or kdEMC).
Activation of Mer Lead to Dissociation of Mer/Vav1 Complex
and Vav1 Tyrosine Phosphorylation—To confirm Vav1/Mer in-
teractions, EMC-expressing 32D cells were stimulated with
EGF, and increased tyrosine phosphorylation of Vav1 was de-
tected. Surprisingly, Vav1 co-immunoprecipitated with unacti-
vated EMC.3 To study this interaction in more detail, myc-
tagged Vav1 constructs were co-transfected in 293T cells with
EMC or kdEMC. Vav1 was readily detected in Mer immuno-
precipitates from unstimulated cells, but the level of Mer-asso-
ciated Vav1 decreased considerably with ligand stimulation
(Fig. 2A, first panel, lanes 1 and 2). When co-transfected with
kdEMC, Vav1 was present in the kdEMC immunoprecipitates
from both untreated and EGF-treated lysed cells (Fig. 2A, first
panel, lanes 3 and 4). Activation of EMC increased Vav1 tyro-
sine phosphorylation (Fig. 2A, second panel, lanes 1 and 2).
This was not observed in kdEMC-expressing cells (Fig. 2A,
second panel, lanes 3 and 4). Thus, in unstimulated cells Vav1
is, at least in part, constitutively bound to Mer. Ligand activa-
tion and Mer autophosphorylation resulted in dissociation of
tyrosine-phosphorylated Vav1 (compare Fig. 2A, first panel,
lane 2 to second panel, lane 2).
Upon co-transfection, the carboxyl-terminal SH3-SH2-SH3,
CVav, was also readily detected in EMC immunoprecipitates
from unstimulated cells and was tyrosine-phosphorylated and
released from this association upon Mer stimulation (Fig. 2B,
second panel). This indicates that at least one site for Mer-de-
pendent Vav1 tyrosine phosphorylation differs from the N-
terminal Tyr-174 known to be phosphorylated by LCK (21).
When co-transfected with kdEMC, CVav was bound to Mer
regardless of ligand addition (Fig. 2B, first panel) and was not
tyrosine-phosphorylated. The construct AVav encompassing
the amino-terminal half of the molecule neither interacted with
Mer nor was tyrosine-phosphorylated when coexpressed with
Mer that had been ligand activated (Fig. 2C). This suggests
that the SH3-SH2-SH3 region of Vav1 is sufficient for (i) inter-
action with, (ii) tyrosine phosphorylation by, and (iii) release
from Mer.
The Vav1 SH2 Domain Interacts with Mer in a Phosphoty-
rosine-independent Manner—To further define interacting do-
mains three more Vav1 constructs were co-expressed with
EMC or kdEMC. Vav1 lacking the carboxyl-terminal SH3,
DVav SH3, behaved in a fashion similar to full-length Vav1
(Fig. 3A, first panel, lanes 1 and 2). However deletion of the
SH2 domain abolished Mer/Vav1 interaction. For example de-
letion of the carboxyl-terminal SH2-SH3 domains produced a
construct, BVavSH2-SH3, that neither associated with Mer nor
was tyrosine-phosphorylated (Fig. 3B, first panel, lanes 1 and
2). JVavSH2, Vav1 with just the SH2 deleted, neither inter-
acted with Mer nor was it tyrosine-phosphorylated (Fig. 3C,
first and second panels, lanes 1 and 2). These results, paradox-
ically, implicate the SH2 domain in a phosphotyrosine-inde-
pendent Mer/Vav1 association.
SH2 domains possess a highly conserved arginine residue,
which extends up from an interior location in the domain to3 N. P. Mahajan and H. Shelton Earp, unpublished results.
FIG. 2. Full-length Vav1 is constitutively associated with un-
phosphorylated Mer. Following co-transfection of EMC or kdEMC
with Vav1 (A) or Vav1 deletion constructs (B and C), lysates from
unstimulated or EGF-stimulated cells were immunoprecipitated (IP)
using anti-Mer, anti-myc, or anti-pTyr antibodies as indicated. The
immune complexes were electrophoresed, transferred, and immuno-
blotted (IB) with anti-myc, anti-Mer, or anti-pTyr antibodies. Molecular
weights are displayed on the left of each panel. A, Vav1 is phosphoryl-
ated in an EGF-dependent manner and no longer co-immunoprecipi-
tated with EMC. kdEMC is not phosphorylated and maintains its
association with Vav1 even after ligand binding. B, the C terminus of
Vav1 behaves like full-length Vav1 upon co-transfection with EMC or
kdEMC. C, the amino terminus of Vav1 is neither bound nor phospho-
rylated by EMC
FIG. 3. The SH2 domain of Vav1 interacts with Mer in a phos-
photyrosine-independent manner. EMC or kdEMC were co-trans-
fected with DVavSH3 (A), BVavSH2-SH3 (B), and JVavSH2 (C). Lysates
from unstimulated or EGF-stimulated were immunoprecipitated and
analyzed as described in Fig. 2. A, the mutant lacking the terminal SH3
domain, DVavSH3, behaved like the Vav1 C terminus. B and C, deletion
of terminal SH2-SH3 domains BVavSH2-SH3, or the SH2 domain itself
JVav, resulted in loss of association with or phosphorylation by Mer.
GEF Vav1 and the Mer Receptor Tyrosine Kinase 42599
interact with the phosphate group of the phosphotyrosine (22–
25). Mutation of this arginine results in loss of phosphotyrosine
binding and impaired Ras activity in Shc (26). To further con-
firm the unusual phosphotyrosine-independent Vav1 binding
to Mer, we mutated Vav1 arginine 696 to alanine (R696A, Fig.
1B). To test the R696A binding properties, it was co-expressed
with the full-length EGF receptor. As expected, R696A did not
interact with phospho-EGF receptor (Fig. 4A, first panel, lanes
3 and 4), whereas wild-type Vav1 interacted with EGFR in an
EGFR phosphotyrosine-dependent manner (Fig. 4A, first
panel, lanes 1 and 2). In contrast, R696A bound to both EMC
and kdEMC irrespective of Mer activation (Fig. 4B, first panel).
Thus, Vav1 recruitment to Mer in unstimulated cells is not the
product of a small amount of the tyrosine-phosphorylated Mer
attracting Vav1. Interestingly, the R696A mutant became ty-
rosine-phosphorylated by activated Mer presumably due to its
contiguity with the active Mer kinase; however, the mutant
does not appear to dissociate from Mer as well as wild-type
Vav1 (compare Fig. 2A, first panel with Fig. 4B, first panel)
even though Vav1 became tyrosine-phosphorylated. This may
indicate that the SH2 pocket region is involved in Vav1 disso-
ciation from tyrosine-phosphorylated Mer.
To ascertain whether the interaction between SH2 domain of
Vav1 and Mer observed in multiple immunoprecipitation ex-
periments is direct, the Mer cytoplasmic domain was subcloned
into bacterial expression vector PGEX4T (Fig. 1A), and the
resultant 75-kDa GST fusion protein was expressed and puri-
fied using glutathione beads (GST-Mer in Fig. 4C, third panel).
In addition, Vav1 construct LVav, encompassing SH3-SH2-
SH3 domains, and KVav deleting the SH2 domain and leaving
the two SH3 domains were subcloned with hexahistidine tags
into a baculovirus expression vector (Fig. 1B). Both Vav do-
main-containing proteins were expressed in insect cells, puri-
fied (Fig. 4C, second panel), and used for in vitro binding assay
(Fig. 4C, first panel). Fifty nM purified LVav and KVav was
immobilized on Talon beads, and the beads alone or beads with
Vav1 domains were incubated with purified GST-Mer (50 nM).
After tumbling for 1 h, and washing three times, the bound
GST-Mer was detected after boiling the Talon beads in SDS, gel
electrophoresis, transfer, and anti-Mer immunoblotting (Fig.
4C, first panel). Only the LVav, which possesses the Vav1 SH2
domain, interacted with Mer with sufficient affinity to allow
detection, whereas KVav, which lacked the SH2 domain, failed
to interact with the purified GST-Mer intracellular domain
(Fig. 4C, first panel, lanes 3 and 2, respectively). Although this
does not preclude the involvement of other molecules in the
intracellular association of Mer and Vav, it does indicate that
the interaction is at least partially direct.
Carboxyl-terminal Region of the Mer Kinase Domain Is In-
volved in Vav1 Interaction—To determine the region within
Mer that is recognized by Vav1, six deletion constructs of Mer,
A-FMer (Fig. 5A), were made and were co-expressed with myc-
tagged full-length Vav1. Our Mer polyclonal antibody was
raised against the carboxyl-terminal region and recognized
A-CMer, EMer, and FMer but not DMer (Fig. 5B, third panel),
which lacks this region. To perform co-immunoprecipitation
assay with DMer, anti-EGFR antibody (clone #1382) was used,
and DMer was detected using a commercial anti-Mer antibody
(Mer Ab2) raised against polypeptide to the region upstream of
kinase domain contained in DMer (Fig. 5B, fourth panel, lane
4). The results show that Vav1 binds to A, B, CMer, but not
DMer (Fig. 5B, first panel, lane 4), placing at least one impor-
tant site of interaction carboxyl-terminal to amino acid 696.
Two other deletions EMer and FMer, were 65 and 87 amino
acids shorter than CMer; both EMer and FMer failed to inter-
act with Vav1 (Fig. 5B, first panel, lanes 5 and 6).
Mer Activation Stimulates GDP to GTP Exchange in RhoA
Family Members—Tyrosine-phosphorylated Vav1 can catalyze
GDP/GTP exchange in Rho family members, e.g. Rac1, Cdc42,
FIG. 4. Vav1 Arg-696 mutant was constitutively associated
with Mer. A, the EGFR was co-transfected with Vav1 or the R696A
mutant, a mutation designed to abolish SH2 domain-phosphotyrosine
interaction. Lysates were immunoprecipitated using anti-EGFR anti-
bodies, and immune complexes were analyzed as in Fig. 2 using anti-
myc, anti-pTyr, and anti-EGFR antibodies. EGF-dependent, EGFR ty-
rosine phosphorylation was observed and resulted in Vav1/EGFR
interaction in the phosphotyrosine-dependent fashion. As expected, the
R696A mutant prevented Vav1/EGFR phosphotyrosine-dependent in-
teraction. B, EMC or kdEMC were co-expressed with Vav1 R696A.
Lysates were immunoprecipitated and analyzed as above. In contrast to
the EGFR, R696A Vav1 was constitutively associated with EMC. Li-
gand treatment resulted in Mer and R696A Vav1 tyrosine phosphoryl-
ation, but R696A failed to dissociate from EMC. C, in vitro binding
assay of Mer and Vav1. LVav and KVav purified from the baculovirus
expression system were bound to Talon beads. Purified GST-Mer pro-
tein was incubated with the Talon beads, unbound protein was washed,
and beads were boiled, separated on SDS-PAGE, then immunoblotted
with anti-Mer antibodies.
GEF Vav1 and the Mer Receptor Tyrosine Kinase42600
and RhoA (27). These proteins when in their GTP-bound form
regulate myriad functions, including actin organization, cell
adhesion, cell motility membrane trafficking, gene expression,
etc. Their crucial role in plasma membrane and cytoskeletal
remodeling during phagocytosis has been well established (28–
30). Rac1 and Cdc42 act at distinct stages to promote actin
filament assembly and organization at the site of particle in-
gestion, whereas RhoA, though recruited to the attachment
site, may participate indirectly in the particle ingestion process
(28). First we determined whether regulation of Vav1 tyrosine
phosphorylation by the Mer chimera stimulated GDP/GTP ex-
change on Rho family members, using 32D cell lines stably
expressing EMC or kdEMC (32D cells express neither Mer nor
the EGF receptor). EGF stimulated EMC tyrosine phosphoryl-
ation but not that of kdEMC (Fig. 6, first panel). Analysis of
GTP-bound Rac1, Cdc42, and RhoA was performed 20 or 30
min after Mer chimera activation, followed by cell lysis and
“pull down” of GTP-bound Rac1 and Cdc42 with GST-PBD
beads and RhoA using GST-RBD beads. Mer tyrosine kinase
activation in EMC cells stimulated accumulation of GTP-bound
Rac1, Cdc42, and RhoA (Fig. 6, third, fifth, and seventh panels;
lanes 1 and 2). The cells expressing kdEMC exhibited no such
increase (Fig. 6, third, fifth, and seventh panels; lanes 3 and 4).
Mer Activation in Isolated Primary Human Monocytes Stim-
ulates Vav1 Tyrosine Phosphorylation, Vav1 Dissociation from
Mer, and GDP/GTP Exchange on Rho Family Members—Mono-
cytes/macrophages, isolated from human blood, were used to
confirm the regulation of Vav1 binding and Rho family mem-
bers by full-length Mer in a physiologically relevant system.
These cells express both Mer and Vav1. In monocytes/macro-
phages Gas6 (150 nM) activated endogenous Mer and produced
Vav1 tyrosine phosphorylation (Fig. 7A, first and third panels).
Gas6 stimulation also produced substantial GDP/GTP ex-
change in all the three members of RhoA family members,
Rac1, Cdc42, and RhoA (Fig. 7A, fifth, seventh, and ninth pan-
els). Untreated monocytes/macrophages had low levels of GTP-
bound RhoA family members and Vav1 tyrosine
phosphorylation.
Lastly, we demonstrated that Mer binds Vav1 constitutively
in human monocytes and the Gas6-mediated activation of en-
dogenous Mer resulted in Vav1 dissociation. Vav1 bound Mer in
untreated monocytes/macrophages (Fig. 7B). Treatment with
Gas6 (150 nM) resulted in tyrosine phosphorylation of both
endogenous Mer and Vav1 (Fig. 7B, second and fourth panels).
Furthermore, Gas6 treatment of monocyte/macrophages de-
creased Vav1 binding to tyrosine-phosphorylated Mer, confirm-
ing the previous observations with EMC in 293T and 32D cells.
DISCUSSION
A Mer splice acceptor site mutation in the RCS rat strain
(12), Mer mutations in at least three human kindreds (16), and
gene-targeted mouse Mer deletion (8) all result in progressive
loss of vision due to defective phagocytosis of shed photorecep-
tor material by retinal pigment epithelial (RPE) cells. Studies
of the immune system in gene-targeted Mer mice reveal a
crucial role for Mer in the recognition and/or initiation of se-
lective phagocytosis of apoptotic cells by macrophages (9). De-
layed apoptotic cell clearance and lupus-like autoimmunity
was demonstrated in mice lacking Mer (11). An even more
severe immune dysregulation is seen in the triple-mutant mice
lacking Mer, Axl, and Tyro-3; these mice exhibit high levels of
apoptotic cells and debris in organs, as well as a profound
immune auto-activation syndrome (10). How Mer leads to the
selective, local cytoskeletal-mediated uptake of extracellular
FIG. 5. Vav1 recognize carboxyl-terminal region of Mer. A, sche-
matic of Mer, Mer chimera, and various intracellular regions represent-
ing constructs used for co-immunoprecipitation assay. A-FMer con-
structs were co-transfected with Vav1 in 293T cells, and lysates were
immunoprecipitated using anti-Mer (in the cases of A-CMer, EMer, and
FMer) or anti-EGFR (in the case of DMer) antibodies. Immune com-
plexes were analyzed using anti-myc, anti-Mer, and anti-Mer Ab2 an-
tibodies. B, Vav1 co-immunoprecipitated with A, B, and CMer but failed
to bind DMer, EMer, and FMer.
FIG. 6. Mer signaling stimulates guanine nucleotide exchange
in 32D cells. In 32D cells, ligand activation of Mer stimulated accu-
mulation of GTP-bound Rac1, RhoA, and Cdc42. kdEMC was without
effect. 32D cell lines stably expressing EMC or kdEMC were treated
with EGF; ligand-dependent, EMC tyrosine phosphorylation was ob-
served. GTP-bound Rac1, RhoA, and Cdc42 were assessed as described
under “Experimental Procedures.”
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apoptotic material bound to a small area of the cell membrane
is unknown.
Monocyte and macrophages use multiple receptors to engage
apoptotic cells and presumably to trigger their phagocytosis
(31, 32). Because general particle phagocytosis is normal in
Mer monocytes, distinct signaling cascades must be initiated by
different particles or materials; these signals need to selec-
tively stimulate local cytoskeletal rearrangement. It is very
likely that, based on type of phagocytic receptor engaged in
particle internalization, distinct signaling cascade would be
triggered, leading to activation of specific member/s of Rho
GTPase subfamily. Rac1, Cdc42, and RhoA activation leads to
different biological consequences that are associated with
phagocytosis, and this separate or coordinate regulation may
define distinct types of phagocytosis (28). In 32D cells, express-
ing the Mer chimera, EGF activation stimulated GDP/GTP
exchange on Rac1, Cdc42, and RhoA, whereas in isolated pri-
mary human monocyte/macrophages, increases in GTP-bound
RhoA, Rac1, and Cdc42 were all stimulated by Gas6 addition.
Whether regulation of all the three Rho family members occurs
via a Mer/Vav1 process remains to be determined.
To speculate further on a specific mechanism for Mer in-
volvement in clearing apoptotic material, it is important to
know that apoptotic cells externalize membrane phosphatidyl-
serine (PS), which after externalization can bind to a specific
PS receptor on the macrophage surface (33). Gas6, a Mer li-
gand, also has an affinity for PS (34) and Gas6 has recently
been shown to speed ingestion of apoptotic material in pig-
mented retinal epithelial cells (13). Together PS and Gas6
could form a complex ligand activating local cytoskeletal
changes through the PS receptor and Mer. The fact that un-
stimulated Mer sequesters Vav1 and can release it upon acti-
vation provides an interesting potential mechanism for regu-
lating the intense local control of RhoA, Rac1, and Cdc42
needed to initiate cytoskeletal engulfment of apoptotic mate-
rial. Mer may hold Vav1 in readiness, releasing it and activat-
ing its GEF activity upon sensing local binding of apoptotic
material (see Fig. 8 for model).
Tyrosine kinase signaling pathways responsible for the rec-
ognition and ingestion of apoptotic cells by both professional
and non-professional phagocytes may be evolutionarily con-
served (35, 36). Indeed, engulfment of apoptotic cells in Cae-
norhabditis elegans is controlled by the genes ced-2 and ced-10,
which encode proteins similar to the human adaptor protein
CrkII and the human GTPase Rac, respectively (35). Whether
other intermediate steps and/or conserved molecules are in-
volved in the proposed (Fig. 8) Mer, Vav1, and Rho family
member process that we predict controls monocyte/macrophage
apoptotic cell ingestion remains to be determined.
SH2 domains are typically found in multidomain signaling
proteins, where they are involved in protein-protein interac-
tion. It has been thought that all large multidomain adaptor or
signaling proteins with SH2 domain bind with high affinity to
specific phosphorylated tyrosines, creating a “ligand” for the
SH2 interaction. Recently a few exceptions to this concept have
been reported suggesting an expanded paradigm for SH2 do-
main function, a phosphotyrosine-independent, SH2 domain
interaction. The X-linked lymphoproliferative-disease gene
product SAP, a small protein that consists almost entirely of
one SH2 domain, interacts with the unphosphorylated SLAM
(36). Syk, a non-receptor tyrosine kinase was observed to asso-
ciate with the 3 integrin cytoplasmic tail through a phospho-
tyrosine-independent process involving the tandem SH2 do-
main region of Syk (37).
Here we find through deletion analysis that the SH2 domain
of Vav1 interacts with an unphosphorylated Mer receptor ty-
rosine kinase. A more selective approach in which mutation of
the phosphotyrosine coordinating Arg-696 to Ala confirmed
that the Mer/Vav1 interaction was SH2 domain-dependent but
phosphotyrosine-independent. Phosphorylation of Mer appears
to eject Vav1 from this constitutive interaction, a process that
involves an intact functional SH2 domain and did not occur
after ligand stimulation of kinase-dead EMC (Fig. 2A). Inter-
estingly, the Vav1 mutant R696A was tyrosine-phosphorylated
by the activated EMC to which it is bound but failed to disso-
ciate from EMC after ligand treatment (Fig. 4B). Therefore, the
Vav1 carboxyl terminus phosphorylation by Mer is only one
part of the proposed mechanism, the Vav1 SH2 pocket region
must play a significant role in dissociation from phosphoryl-
ated Mer. The physical insertion of a Mer phosphotyrosine
residue may be needed to alter Vav1 conformation reversing
FIG. 7. Gas6-mediated activation of Mer leads to tyrosine phos-
phorylation and dissociation of bound Vav1 and GDP/GTP ex-
change in monocytes/macrophages. A, in monocytes/macrophages,
activation of endogenous Mer in response to 10 min of Gas6 treatment
resulted in tyrosine phosphorylation of endogenous Vav1. The subse-
quent increase in GTP-bound Rac1, Cdc42, and RhoA were assessed as
described under “Experimental Procedure.” B, monocytes/macrophages
derived from human blood were treated with 150 nM Gas6 for 10 min
decreasing Vav1 binding to Mer. Lysates were immunoprecipitated
using anti-Mer or anti-Vav1 antibodies, and the immune complexes
were electrophoresed, transferred, and immunoblotted with anti-pTyr,
anti-Mer, or anti-Vav1 antibodies.
FIG. 8. Constitutive Mer/Vav1 binding provides apoptotic cell
recognition and control of GEF activity: a model.
GEF Vav1 and the Mer Receptor Tyrosine Kinase42602
the affinity for Mer. In essence, the opposite of the SH2 domain
function in most examples.
As indicated above, other proteins may be involved in stabi-
lizing the Mer/Vav1 complex or in regulating Vav1 dissociation.
The Mer-dependent tyrosine phosphorylation of Vav1 in the
SH3-SH2-SH3 region (see CVav tyrosine phosphorylation, Fig.
2B) is not sufficient to eject Vav1 from the complex (R696A,
Fig. 4B). An intact SH2 phosphotyrosine site appears to be
necessary. We do not yet know what role the carboxyl-terminal
Vav1 tyrosine phosphorylation plays in activating guanine nu-
cleotide exchange function or relocalizing Vav1 to its site of
action. However, the novel interaction described herein, an
SH2-dependent, phosphotyrosine-independent constitutive
binding of Vav1 to Mer, does provide a mechanism for localizing
Vav1 GEF action to the site surrounding the cell surface inter-
face at which Mer has been activated by apoptotic cell binding.
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